Providers

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.

The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.

This observational evaluation compared an adult medical care coordination intervention with usual care and found that the intervention was associated with significant improvements in patient activation.

The CDC urges all travelers to be fully vaccinated against measles amid rising cases in the US, some linked with international travel.

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.

Iron deficiency anemia increased the risk of death from any cause, while non-iron deficiency anemia was linked with an increased risk of cardiovascular disease (CVD)-related death in rheumatoid arthritis.

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.

Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need for careful interpretation of results and multidisciplinary collaboration.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The rate of rheumatoid arthritis (RA) has increased over the last 32 years, with certain groups of interest facing higher burden, finds a new analysis.

New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.